Kids Huff Dust-Off From the Hardware Store. The Federal Government Is Only Now Getting Around to a Ban.

She was fourteen. She took the can from under the sink — the compressed air can they used to clean keyboards, the kind sold in any office supply store for six dollars. She held the nozzle to her lips and inhaled. The high came in under five seconds: a rushing, spinning, briefly oceanic feeling, gone inside two minutes, chased by a crushing headache. She did it again. There were 1,000-plus deaths from aerosol inhalant products in the United States between 2012 and 2021. She did not know she was in that statistical population. Nobody told her the can had killed people. The warning label said: “Intentional misuse by deliberately concentrating and inhaling the contents can be harmful or fatal.”

“Can be.”

The U.S. Consumer Product Safety Commission proposed declaring aerosol duster products containing more than 18 milligrams of HFC-152a or HFC-134a — the pressurized gases that produce the rushing high — as banned hazardous substances. The data supporting the proposal documented 1,000 deaths and approximately 21,700 treated injuries from aerosol duster inhalation between 2012 and 2021 in the United States alone.

Inhalants are the most accessible intoxicant in America — sold legally, unscheduled, nearly invisible in the treatment system. The federal government’s first serious regulatory action in decades covers a fraction of what teenagers actually use.

The CPSC proposal is a start. It addresses two compounds in one product category. Inhalants are not one product category.

What “Inhalants” Actually Means

The clinical category is broader than most providers’ intake assessments acknowledge: aerosol sprays (the dusters, but also hairspray, cooking spray, paint, Scotchgard), volatile solvents (glue, correction fluid, paint thinner, nail polish remover), gases (butane lighters, propane tanks, whipped cream dispensers — nitrous oxide, the gas in those canisters — and, increasingly, medical anesthetics accessed illicitly), and nitrites (amyl nitrite, isobutyl nitrite, the “poppers” marketed as room deodorizers). Each of these classes produces intoxication through a different chemical mechanism. What they share is that they’re cheap, legal, available at any hardware or grocery store, and they work in under a minute.

The rush — whatever you call it, the spin, the head high, the brief dissociation — comes from the same physiological mechanism that makes these substances uniquely dangerous: hypoxia, often combined with direct cardiac sensitization. The heart, suddenly running with less oxygen and disrupted by the solvent’s effect on membrane channels, can go into ventricular fibrillation. This is called Sudden Sniffing Death Syndrome. It can happen on a first use. It can happen on a hundredth use. It can happen to someone who has never had a cardiac risk factor in their life.

There is no naloxone for inhalant overdose. There is no reversal agent. There is oxygen, and there is calling 911, and there is hoping the ventricles restart.

The Policy Vacuum

You cannot schedule a can of compressed air. That’s the fundamental regulatory problem. Inhalants are not controlled substances because they are not substances manufactured for psychoactive use. They are consumer products that happen to be psychoactive when misused. The Controlled Substances Act was written for drugs. It has essentially no purchase on the home-supply-store shelf.

What exists instead is a patchwork: the Federal Hazardous Substances Act, which authorizes the CPSC to declare products hazardous — but only based on evidence about the specific formulation, not the use pattern. The Volatile Substance Abuse Prevention Act, a model law some states have adopted, empowers local retailers to refuse to sell to minors purchasing products associated with inhalant misuse. It has no federal implementation. The SAMHSA NSDUH survey has tracked inhalant use since its first iteration — and even changed its methodology in 2024, altering the question wording from “for kicks or to get high” to “for fun or to get high,” a shift that appears to have affected adolescent reporting rates, making trend analysis harder precisely when the data matters most.

The Volatile Substance Abuse Prevention Act, a model law some states have adopted, empowers local retailers to refuse to sell to minors purchasing products associated with inhalant misuse.

The CPSC aerosol-duster proposal targets HFC-152a and HFC-134a. It does not address butane, propane, nitrous oxide, amyl nitrite, or any of the solvent class. A teenager who cannot buy keyboard cleaner will be able to buy a can of whipped cream, a butane lighter refill, or a bottle of correction fluid. The geography of inhalant access is not a supply-chain problem. It is a feature of being a substance class that was never designed to be a drug.

Who Uses Inhalants — and Why Access Is the Point

Inhalants are a substance of adolescent poverty and adolescent geography. The NSDUH data consistently shows that inhalant use peaks in the 12–17 age group and that it skews toward lower-income communities and rural areas — places where the alternatives (alcohol, cannabis, even fentanyl) are harder to get or more expensive. In those demographics, inhalants are not a gateway to other drugs. They are what’s available. They are what six dollars at the dollar store buys when you’re fourteen and bored and living somewhere with no after-school programs and no adults paying attention.

If you are doing intake assessments in a treatment program and your intake screen doesn’t specifically ask about inhalant use, you are missing a significant portion of the adolescent population you serve. Arizona AHCCCS spent $582.3 million on SUD treatment services in State Fiscal Year 2025. That number tracks opioid treatment, alcohol treatment, stimulant treatment. The inhalant-specific treatment infrastructure in the state — the counselors trained specifically in inhalant-use disorder, the programs that understand the neurological sequelae of chronic solvent exposure — is minimal.

The Treatment Gap Nobody Discusses

Inhalant use disorder is clinically distinct from other SUDs in ways that matter for treatment. Chronic inhalant exposure causes neurological damage — white matter lesions, cognitive impairment, cerebellar ataxia — that presents as learning disabilities, memory problems, and coordination issues that get misattributed to other causes. Adolescents with chronic inhalant use disorder often present to treatment programs with cognitive profiles that look like traumatic brain injury because, neurologically, that’s close to what they are.

There are no FDA-approved medications for inhalant use disorder. The evidence base for behavioral interventions is thin. A 2026 meta-analysis of EMDR for substance use disorders found significant effects on craving, PTSD, and depression — conditions that frequently co-occur with inhalant use disorder — but the study populations didn’t focus specifically on inhalants. Trauma-informed care is the intervention that makes the most clinical sense given what we know about who inhalant users are and why they use.

For a provider treating an adolescent with inhalant use disorder, the right clinical question is usually not “how do we stop the inhalant use” but “what is this person managing that inhalants are the fastest, cheapest, most accessible answer to.”

The History We Keep Not Learning From

The policy neglect of inhalants is not new. In the 1960s, glue-sniffing among teenagers — specifically model airplane cement containing toluene — was recognized as a public health problem. The response was voluntary reformulation by some manufacturers and consumer-product warnings. The voluntary reformulations took decades. Model cement is still sold.

In the 1980s, concern about amyl nitrite (“poppers”) among gay men prompted the FDA to regulate them as over-the-counter inhalants requiring a prescription. The industry reformulated to isobutyl nitrite and renamed them room deodorizers, which required no regulation. The poppers market expanded. The name changed. The substance didn’t.

The CPSC aerosol-duster proposal — proposed in July 2024, still not finalized — follows a familiar arc: documented deaths, proposed regulatory action, industry comment period, reformulation pressure, a gap between what gets covered and what teenagers actually use. We count deaths in the meantime.

What Providers Should Do, Starting Now

Add inhalants to your intake screen — by name and category: “Have you ever used aerosol sprays, compressed air, paint or glue, whipped cream chargers, or any other household products to get high?” Standard CAGE-AID and AUDIT-C screens don’t capture inhalant use. Adolescent intake assessments that skip this category are systematically missing the cheapest SUD on the market.

Adolescent intake assessments that skip this category are systematically missing the cheapest SUD on the market.

Know that naloxone does not work for inhalant overdose. It is for opioid-receptor-mediated respiratory depression. Inhalant overdose is cardiac and hypoxic. Response is 911 and oxygen, not naloxone. This distinction matters in a community where harm reduction messaging has correctly centered naloxone but hasn’t extended to inhalants.

Screen for cognitive effects. An adolescent presenting with what looks like ADHD, learning disability, or processing difficulties who has a history of inhalant use may have subcortical white matter injury. A neuropsychological evaluation is appropriate before educational or vocational planning.

Raise the policy question with your state health department contact. The CPSC aerosol-duster rule addresses two compounds. The rest of the category is still unaddressed. Arizona providers who are seeing inhalant presentations in their programs have standing to be part of the regulatory comment process.

What Remains

The fourteen-year-old who took the keyboard cleaner from under the sink didn’t know she was in a statistical population. She didn’t know that the warning label saying “can be” fatal was underwriting a silence — a regulatory and clinical silence — that has persisted for sixty years while this substance class kept killing adolescents.

The CPSC ban, if finalized, will remove two chemicals from two products. It will not remove six dollars from a kid’s pocket. The rest of the work — the intake screening, the treatment infrastructure, the cognitive follow-up, the trauma-informed care — is not going to come from a federal register notice. It has to come from providers who know what they’re looking at when a teenager shows up in their program.

Naloxone is still federally funded and available at pharmacies in Arizona. If you work with youth, you know what that resource doesn’t cover. It doesn’t cover this.